XML 23 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity
 3 Months Ended
Dec. 31, 2016
Equity [Abstract]  
Stockholders' Equity

NOTE 5. STOCKHOLDERS’ EQUITY

At December 31, 2016, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share.

At December 31, 2016, 74,413,040 shares of Common Stock were outstanding.  At December 31, 2016, 8,100,085 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead’s 2004 Equity Incentive Plan and 2013 Incentive Plan, as well as for inducement grants made to new employees.

During the three months ended December 31, 2016, 15,652 shares of Series C Preferred Stock were converted into 2,670,990 shares of Common Stock. No preferred stock was outstanding as of December 31, 2016.  

On November 18, 2016, a tranche of 1,745,810 shares was sold to Amgen at a price of $7.16 per share as part of the ARO-LPA Agreement discussed in Note 2 above.  The Company received proceeds of $12.5 million in November 2016.

The following table summarizes information about warrants outstanding at December 31, 2016:

 

Exercise prices

 

Number of 
Warrants

 

 

Remaining
Life in Years

 

$

70.60

 

 

 

94,897

 

 

 

0.4

 

$

2.12

 

 

 

75,000

 

 

 

1.2

 

$

1.83

 

 

 

277,284

 

 

 

1.0

 

$

7.14

 

 

 

80,000

 

 

 

1.5

 

Total warrants outstanding

 

 

527,181